<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03843593</url>
  </required_header>
  <id_info>
    <org_study_id>19-012</org_study_id>
    <nct_id>NCT03843593</nct_id>
  </id_info>
  <brief_title>A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery</brief_title>
  <official_title>Why Do Patients Agree To or Decline Adjuvant Immunotherapy and Are They Satisfied With Their Decision?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out what patients consider when deciding whether or not
      to receive adjuvant treatment, and how patients feel about their decision after one year.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>self-reported factors patients consider in deciding whether or not to undergo adjuvant therapy</measure>
    <time_frame>1 year</time_frame>
    <description>Factors considered are gleaned from the Acceptance/Declination Survey</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>self-reported quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>as captured by FACT-M, as well as treatment satisfaction. Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11 - FACT-M is a 51- item patient-self report measure for the assessment of quality of life (QOL) in patients with American Joint Committee on Cancer stages I through IV melanoma.The FACT-M incorporates a recall period of 7-days and a five-point Likert-type scale (i.e., 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cutaneous Melanoma</condition>
  <arm_group>
    <arm_group_label>Melanoma patients</arm_group_label>
    <description>This is a pilot prospective study to identify the factors patients consider in deciding whether or not to undergo adjuvant therapy. Patients are eligible regardless of whether they decide to accept adjuvant therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Demographics Questionnaire</intervention_name>
    <description>A brief questionnaire will collect basic demographic information (i.e., age, gender, racial background, ethnicity, employment status, marital status) at time of enrollment.</description>
    <arm_group_label>Melanoma patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Adjuvant Treatment Beliefs Scale10</intervention_name>
    <description>This brief PRO measure asks patients to indicate the likelihood, using a 5-point Likert type scale (1 [definitely not], 2 [probably not], 3 [maybe], 4 [probably], 5 [definitely]) of six positive (e.g., reduced risk of recurrence, greater chance of being cured) and five negative outcomes (e.g., side effects, health status) of adjuvant treatment.</description>
    <arm_group_label>Melanoma patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11</intervention_name>
    <description>FACT-M is a 51-item patient-self report measure for the assessment of quality of life (QOL) in patients with American Joint Committee on Cancer stages I through IV melanoma.</description>
    <arm_group_label>Melanoma patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13</intervention_name>
    <description>FACIT-TS-G is a brief, 8-item self-administered measure designed to assess general treatment satisfaction in patients.</description>
    <arm_group_label>Melanoma patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Decisional Regret14</intervention_name>
    <description>This is a set of 5 questions examining level of regret for treatment decisions (in this case, decision to pursue adjuvant therapy), with answers scored on a 5-point Likert-type scale (i.e., 1 [Strongly Agree], 2 [Agree], 3 [Neither Agree Nor Disagree], 4 [Disagree], 5 [Strongly Disagree].</description>
    <arm_group_label>Melanoma patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Clinician Preference for Treatment</intervention_name>
    <description>This is a single item to be completed by Medical Oncologists that will indicate their preference as to whether they prefer that their patient accepts nivolumab therapy.</description>
    <arm_group_label>Melanoma patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Potential research participants will be identified by members of the Melanoma service, the
        patientsâ€Ÿ treatment team, or the PI.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with stage IIIB, IIIC, IIID, or IV (AJCC, 8th edition) cutaneous melanoma
             rendered free of disease by surgical resection.

          -  Patients are being offered adjuvant nivolumab therapy

          -  Patient has not yet formally discussed their treatment options with their Medical
             Oncologist.

          -  Age 18 or older.

          -  Ability to speak and read English because we do not have the resources to translate
             materials into other languages.

        Exclusion Criteria:

          -  Patient not currently free of disease.

          -  Candidate for adjuvant dabrafenib/trametinib therapy.

          -  Patients who have received prior checkpoint inhibitor therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Chapman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Chapman, MD</last_name>
    <phone>646-888-4162</phone>
    <email>chapmanp@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Atkinson, PhD</last_name>
    <phone>646-888-0089</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Chapman, MD</last_name>
      <phone>646-888-4162</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Chapman, MD</last_name>
      <phone>646-888-4162</phone>
    </contact>
    <contact_backup>
      <last_name>Thomas Atkinson, PhD</last_name>
      <phone>646-888-0089</phone>
    </contact_backup>
    <investigator>
      <last_name>Paul Chapman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2019</study_first_posted>
  <last_update_submitted>October 23, 2019</last_update_submitted>
  <last_update_submitted_qc>October 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Decline Adjuvant Immunotherapy</keyword>
  <keyword>Agree To Adjuvant Immunotherapy</keyword>
  <keyword>19-012</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

